For nasopharyngeal cancers ... The key difference typically lies in duration – throat cancer symptoms generally don’t improve with time or standard treatments for common ailments.

Adding penpulimab to chemotherapy can improve progression-free survival for patients with recurrent or metastatic nasopharyngeal carcinoma, data suggest.

April 25, 2025 — The FDA has approved a new drug for adults with a rare type of head and neck cancer known as non-keratinizing nasopharyngeal carcinoma (NPC) after studies showed that ...

Penpulimab is approved for multiple indications in China, but this marks the first US approval for the novel monoclonal ...

The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma. The United States Food and Drug Administration (FDA) has approved ...